NASDAQ:VNDA

Vanda Pharmaceuticals Stock News

etoro logo Buy VNDA
*Your capital is at risk
$5.10
-0.0800 (-1.54%)
At Close: Jul 31, 2026
Vanda confirmed it received several unsolicited acquisition offers from Future Pak. The company's board rejected these proposals, stating that Vanda is worth more than the offered price.
WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited duratio
Vanda Pharmaceuticals Inc on Wednesday said it is rejecting a takeover proposal from Future Pak, a privately-held contract manufacturer and packager of pharmaceuticals, as it significantly undervalues
Board Determined Unsolicited Takeover Proposals Significantly Undervalue the Company No Shareholder Action Required at This Time WASHINGTON , April 17, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals (NASDAQ: VNDA ) stock is rising higher on Wednesday after the biopharmaceutical company received a firm acquisition proposal from Future Pak LLC. Vanda Pharmaceuticals has recei
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak LLC (“Future Pak”) today announced that it has submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda
Vanda Pharmaceuticals (VNDA) concluded the recent trading session at $4.06, signifying a -1.46% move from its prior day's close.
Vanda Pharmaceuticals (VNDA) closed at $4.28 in the latest trading session, marking a -1.83% move from the prior day.
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) announces the FDA's approval of Fanapt for the acute treatment of bipolar I disorder in adults. The stock rises 30.4%.
Shares of Vanda Pharmaceuticals VNDA, -5.10% jumped 33% to $5.23 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associa
The U.S. FDA approved Vanda Pharmaceuticals' drug to treat manic and mixed episodes associated with a type of bipolar disorder, the company said on Tuesday, marking the second approval for the treatme
Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
Vanda Pharmaceuticals is trading materially below its holdings of cash and marketable securities (worth almost $7/share). Multiple FDA approvals, if forthcoming, in 2024 could prove to be material cat
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE